الفهرس 
cover EnglishOnly 14 pages are availabe for public view
 |  | from | 237 |  |  |
| | | from | 237 | | |
Abstract
Background despite the standard treatment for advanced nsclc, the overall prognosis is very poor. Attempts to use molecular markers to predict the chemotherapeutic response are rapidly evolving. Methods : prospective analysis of 85 patients with advanced nsclc was conducted in our institute, assessment of ercc1, rrm1 and brca1 ( by elisa and rna extraction) were done before receiving gemcitabin and cisplatin. Results patient with low levels of ercc1 & rrm1 have a better pfs than those with high levels. Conclusions : the importance for continuous search for tailoring the chemotherapy regimens according to molecular markers to reach better survival. Key words nsclc, molecular markers.